CA3046415A1 - Migraine prevention and treatment - Google Patents
Migraine prevention and treatment Download PDFInfo
- Publication number
- CA3046415A1 CA3046415A1 CA3046415A CA3046415A CA3046415A1 CA 3046415 A1 CA3046415 A1 CA 3046415A1 CA 3046415 A CA3046415 A CA 3046415A CA 3046415 A CA3046415 A CA 3046415A CA 3046415 A1 CA3046415 A1 CA 3046415A1
- Authority
- CA
- Canada
- Prior art keywords
- migraine
- compound
- symptoms
- salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16206018 | 2016-12-21 | ||
| EP16206018.0 | 2016-12-21 | ||
| EP17154258 | 2017-02-01 | ||
| EP17154258.2 | 2017-02-01 | ||
| PCT/EP2017/083880 WO2018115158A1 (en) | 2016-12-21 | 2017-12-20 | Migraine prevention and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3046415A1 true CA3046415A1 (en) | 2018-06-28 |
Family
ID=61005774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3046415A Pending CA3046415A1 (en) | 2016-12-21 | 2017-12-20 | Migraine prevention and treatment |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11166928B2 (https=) |
| EP (2) | EP3558280B1 (https=) |
| JP (2) | JP7514457B2 (https=) |
| KR (1) | KR102610870B1 (https=) |
| CN (1) | CN110087642B (https=) |
| AU (2) | AU2017384625B2 (https=) |
| CA (1) | CA3046415A1 (https=) |
| DK (1) | DK3558280T3 (https=) |
| ES (1) | ES2948609T3 (https=) |
| FI (1) | FI3558280T3 (https=) |
| HR (1) | HRP20230851T1 (https=) |
| HU (1) | HUE062536T2 (https=) |
| LT (1) | LT3558280T (https=) |
| PL (1) | PL3558280T3 (https=) |
| RU (1) | RU2753057C9 (https=) |
| SI (1) | SI3558280T1 (https=) |
| WO (1) | WO2018115158A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| EP3558280B1 (en) * | 2016-12-21 | 2023-06-07 | Universitäts-kinderspital Beider Basel | Migraine prevention and treatment |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| BR112021015861A2 (pt) * | 2019-03-22 | 2021-10-05 | Société des Produits Nestlé S.A. | Métodos que usam administração de triglicerídeos de cadeia média (tcm) antes de uma refeição para aumentar a produção de cetonas a partir dos tcms |
| EP3965740A1 (en) | 2019-05-10 | 2022-03-16 | KetoSwiss AG | Ketone bodies enclosed in microbeads |
| EP4656238A3 (de) * | 2019-06-12 | 2026-02-25 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern |
| CN114008014B (zh) * | 2019-06-12 | 2024-03-22 | 凯托利皮克斯治疗有限责任公司 | 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法 |
| WO2021195477A1 (en) | 2020-03-27 | 2021-09-30 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections |
| KR20240037239A (ko) | 2021-07-17 | 2024-03-21 | 케토스위스 아게 | 케톤체 또는 케톤 생성 화합물과 진통제 또는 항산화제의 조합 |
| CN119072305A (zh) | 2022-03-02 | 2024-12-03 | N·V·努特里奇亚 | 用于控制酮症的脂肪酸 |
| CN115590963A (zh) * | 2022-07-13 | 2023-01-13 | 复旦大学（Cn） | 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用 |
| KR102775899B1 (ko) | 2023-12-19 | 2025-02-28 | 한림대학교 산학협력단 | 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0174979A4 (en) * | 1984-03-01 | 1987-11-23 | Vernon Erk | METHOD FOR LOWERING THE BLOOD GLUCOSE LEVEL IN VERBELTIES. |
| JPH0665458A (ja) * | 1992-08-21 | 1994-03-08 | Nippon Oil & Fats Co Ltd | 塩素含有樹脂組成物 |
| US5420335A (en) * | 1993-09-30 | 1995-05-30 | Birkhahn; Ronald H. | Parenteral nutrients based on watersoluble glycerol bisacetoacetates |
| CA2283642C (en) * | 1997-03-17 | 2012-05-15 | Btg International Limited | Therapeutic compositions |
| WO2000015216A1 (en) * | 1998-09-15 | 2000-03-23 | Btg International Limited | Therapeutic compositions (ii) |
| US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US7807718B2 (en) * | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| WO2010084356A1 (en) * | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
| CN103877118A (zh) * | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | 一种由醋丙甲泼尼龙、氧化锌组成的药物组合物 |
| US20160078782A1 (en) * | 2014-09-17 | 2016-03-17 | The Trustees Of Boston College | Glucose Ketone Index for MetabolicTherapy |
| US20180200220A1 (en) * | 2015-07-10 | 2018-07-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources |
| EP3558280B1 (en) * | 2016-12-21 | 2023-06-07 | Universitäts-kinderspital Beider Basel | Migraine prevention and treatment |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US10500182B2 (en) | 2018-01-10 | 2019-12-10 | Robert Firger | Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache |
-
2017
- 2017-12-20 EP EP17832224.4A patent/EP3558280B1/en active Active
- 2017-12-20 ES ES17832224T patent/ES2948609T3/es active Active
- 2017-12-20 FI FIEP17832224.4T patent/FI3558280T3/fi active
- 2017-12-20 HR HRP20230851TT patent/HRP20230851T1/hr unknown
- 2017-12-20 KR KR1020197021346A patent/KR102610870B1/ko active Active
- 2017-12-20 US US16/472,309 patent/US11166928B2/en active Active
- 2017-12-20 EP EP23176972.0A patent/EP4245368A3/en active Pending
- 2017-12-20 WO PCT/EP2017/083880 patent/WO2018115158A1/en not_active Ceased
- 2017-12-20 DK DK17832224.4T patent/DK3558280T3/da active
- 2017-12-20 CN CN201780079158.4A patent/CN110087642B/zh active Active
- 2017-12-20 SI SI201731394T patent/SI3558280T1/sl unknown
- 2017-12-20 AU AU2017384625A patent/AU2017384625B2/en active Active
- 2017-12-20 RU RU2019122562A patent/RU2753057C9/ru active
- 2017-12-20 HU HUE17832224A patent/HUE062536T2/hu unknown
- 2017-12-20 PL PL17832224.4T patent/PL3558280T3/pl unknown
- 2017-12-20 JP JP2019534680A patent/JP7514457B2/ja active Active
- 2017-12-20 LT LTEPPCT/EP2017/083880T patent/LT3558280T/lt unknown
- 2017-12-20 CA CA3046415A patent/CA3046415A1/en active Pending
-
2021
- 2021-06-01 US US17/335,319 patent/US11890264B2/en active Active
-
2022
- 2022-03-07 AU AU2022201565A patent/AU2022201565B2/en active Active
- 2022-08-18 JP JP2022130419A patent/JP2022166218A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110087642B (zh) | 2022-12-27 |
| US20210338618A1 (en) | 2021-11-04 |
| AU2017384625A1 (en) | 2019-06-13 |
| EP4245368A3 (en) | 2024-01-03 |
| FI3558280T3 (fi) | 2023-07-13 |
| US20190374490A1 (en) | 2019-12-12 |
| US11166928B2 (en) | 2021-11-09 |
| AU2022201565A1 (en) | 2022-03-31 |
| EP3558280A1 (en) | 2019-10-30 |
| JP7514457B2 (ja) | 2024-07-11 |
| RU2753057C2 (ru) | 2021-08-11 |
| CN110087642A (zh) | 2019-08-02 |
| JP2022166218A (ja) | 2022-11-01 |
| KR102610870B1 (ko) | 2023-12-06 |
| AU2022201565B2 (en) | 2023-07-06 |
| EP3558280B1 (en) | 2023-06-07 |
| HRP20230851T1 (hr) | 2023-11-10 |
| KR20190099486A (ko) | 2019-08-27 |
| WO2018115158A1 (en) | 2018-06-28 |
| DK3558280T3 (da) | 2023-08-21 |
| HUE062536T2 (hu) | 2023-11-28 |
| JP2020504746A (ja) | 2020-02-13 |
| RU2019122562A (ru) | 2021-01-27 |
| PL3558280T3 (pl) | 2023-10-16 |
| EP4245368A2 (en) | 2023-09-20 |
| RU2019122562A3 (https=) | 2021-01-27 |
| ES2948609T3 (es) | 2023-09-14 |
| SI3558280T1 (sl) | 2023-10-30 |
| US11890264B2 (en) | 2024-02-06 |
| LT3558280T (lt) | 2023-10-10 |
| RU2753057C9 (ru) | 2021-09-10 |
| AU2017384625B2 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201565B2 (en) | Migraine prevention and treatment | |
| Cunnane et al. | Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer’s disease | |
| Pezzoli et al. | Levodopa in Parkinson's disease: from the past to the future | |
| Dupont et al. | Sustained‐release Madopar HBS® compared with standard Madopar® in the long‐term treatment of de novo parkinsonian patients | |
| Nierenberg et al. | Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development | |
| Paoli et al. | Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets | |
| JP2015512418A (ja) | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 | |
| JP2018131470A (ja) | グルコーストランスポータ１欠乏の治療のためのトリヘプタノイン | |
| Auffret et al. | Apomorphine pump in advanced Parkinson's disease: effects on motor and nonmotor symptoms with brain metabolism correlations | |
| Buoli et al. | Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder | |
| Segel et al. | A safety trial of high dose glyceryl triacetate for Canavan disease | |
| Bruno et al. | Acetyl-L-carnitine augmentation of clozapine in partial-responder schizophrenia: a 12-week, open-label uncontrolled preliminary study | |
| KR20180015126A (ko) | 자폐증을 치료하기 위한 조성물 및 방법 | |
| Gordon et al. | Intravenous levodopa administration in humans based on a two-compartment kinetic model | |
| White et al. | Systematic review of the use of ketones in the management of acute and chronic neurological disorders | |
| Bourque et al. | The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys | |
| Mundt-Petersen et al. | Infusional therapies, continuous dopaminergic stimulation, and nonmotor symptoms | |
| Colomer et al. | Valproate-induced hyperammonaemic encephalopathy in a neonate: Treatment with carglumic acid | |
| Sivam et al. | Role of gabapentin enacarbil XR in restless legs syndrome | |
| Polo et al. | Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome | |
| CN114072154A (zh) | 用于治疗精神障碍的加波沙朵和锂的组合物 | |
| White et al. | Novel Metabolic Substrates for Feeding the Injured Brain | |
| Croce | CPTII Deficiency: A Therapeutical Approach | |
| Cunnane et al. | St-Pierre V | |
| HK40065529A (en) | Combination of gaboxadol and lithium for the treatment of psychiatric disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241114 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241114 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250604 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250604 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260114 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260224 |